|Free Dividend Report|
|Stock Splits Calendar|
|MEIP Stock Split History|
|Preferred Stock Newsletter|
|MEIP Options Chain|
|Stock Message Boards|
MEI Pharma (MEIP) has 1 split in our MEIP split history database. The split for MEIP took place on December 19, 2012. This was a 1 for 6 reverse split, meaning for each 6 shares of MEIP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as MEI Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MEIP split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MEI Pharma shares, starting with a $10,000 purchase of MEIP, presented on a split-history-adjusted basis factoring in the complete MEIP split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-8.63%|
|About MEI Pharma|
|MEI Pharma is a late-stage pharmaceutical company focused on the development and commercialization of cancer therapies. Co.'s drug candidate pipeline includes: Zandelisib, an oral, once-daily, selective phosphatidylinositol 3-kinase delta inhibitor for the treatment of B-cell malignancies; Voruciclib, an orally administered cyclin-dependent kinase inhibitor; ME-344, a tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate; and Pracinostat, an oral histone deacetylase inhibitor being evaluated in patients with high or very high-risk myelodysplastic syndrome who are previously untreated with hypomethylating agents. According to our MEIP split history records, MEI Pharma has had 1 split.|
|MEIP Split History Table|
|12/19/2012||1 for 6|
|Healthcare Stock Splits|
|MEIP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: MEIP shares outstanding history